Sendero Wealth Management LLC Sells 3,733 Shares of IQVIA Holdings Inc. $IQV

Sendero Wealth Management LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 7.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 47,403 shares of the medical research company’s stock after selling 3,733 shares during the quarter. IQVIA makes up approximately 1.2% of Sendero Wealth Management LLC’s portfolio, making the stock its 12th largest holding. Sendero Wealth Management LLC’s holdings in IQVIA were worth $10,685,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in IQV. Claret Asset Management Corp raised its stake in shares of IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares in the last quarter. Versant Capital Management Inc boosted its position in IQVIA by 6.3% during the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. Private Advisor Group LLC grew its holdings in IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares during the last quarter. CVA Family Office LLC raised its position in shares of IQVIA by 11.6% in the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 68 shares during the period. Finally, Huntington National Bank raised its position in shares of IQVIA by 7.8% in the third quarter. Huntington National Bank now owns 969 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 70 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IQV. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Royal Bank Of Canada began coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and raised their price target for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Jefferies Financial Group cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and a consensus target price of $229.13.

IQVIA Trading Up 2.1%

Shares of IQV stock opened at $169.05 on Friday. The firm has a market capitalization of $28.69 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 1.60 and a beta of 1.39. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm’s fifty day simple moving average is $188.18 and its 200 day simple moving average is $205.38. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.